

JOURNAL OF CLINICAL RESEARCH BEST PRACTICES

Vol. 2, No. 12, December 2006

"Can You Handle the Truth?"

"PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2006/2007"

PAREXEL International, 2006, 316 pages, \$425

Review by Norman M. Goldfarb

"PAREXEL'S Pharmaceutical R&D Statistical Sourcebook 2006/2007" provides a staggering array of detailed data in over 600 charts, tables and figures about pharmaceutical and biotech research and development.

The authors have scoured the world for informative and useful data and analysis, including some not easily accessible to the general public.

This book has been selected for
[The First Clinical Research Bookshelf](#)
Essential reading for clinical research professionals

The book has five sections:

- R&D Spending (40 pages)
- Products in Development (66 pages)
- Drug Development Costs/Complexity, Development Time, and Success Rates (112 pages)
- Regulatory/FDA Statistics (70 pages)
- International Statistics (28 pages)

Updating the data each year – this is the tenth edition – is a monumental feat. To provide just a taste of the contents:

- The number of drugs in preclinical testing is down 7% from the peak in 2004.
- The number of new molecular entities (NMEs) in Phase II trials is up 82% from 2002, while the number in Phase III trials is flat.
- Once a new drug enters clinical trials, the probability that it will eventually get FDA approval is 37% for genitourinary drugs, but only 16% for respiratory drugs.
- Immunomodulation studies have more than twice the number of procedures per subject than genitourinary studies.

Some of the charts that are new this year reveal:

- Oncology, metabolism/endocrine and anesthesia/analgesia/rheumatology rank 1-2-3 in 2005 IND filings, with a combined share of 41%. These therapeutic areas must be growing, because they comprise only 32% of active INDs.
- As locations for clinical research, China, India and Brazil rank 1-2-3 on subject availability. Russia, Argentina and China rank 1-2-3 on overall low cost.
- Over 1,000 clinical trials in the United States currently employ a genomic technology.

The book is available at <http://www.barnettinternational.com/>

Author

Norman M. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information, consulting and training services. Contact him at 1.650.465.0119 or ngoldfarb@firstclinical.com.